[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"nasal-polyps\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:nasal-polyps":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,9,0,[8,45,75,97,119,144,175,201,228],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100579465","phase-4-biologics-in-chronic-rhinosinusitis-with-nasal-polyposis-100579465",false,"NCT06824649","Biologics in Chronic Rhinosinusitis With Nasal Polyposis","SMART Use of Biologics in Chronic Rhinosinusitis With Nasal Polyposis","CRSwNP","Inclusion Criteria:\n\n* Age \\> 18 years\n* Confirmed diagnosis of chronic rhinosinusitis with nasal polyposis using ICAR-21 (International Consensus Statement 20215) criteria\n* Bilateral nasal polyposis visible on sinonasal endoscopy\n* Nasal polyp score \\> 5\n* Baseline SNOT-22 total score \\> 30\n* Patient elects biologic therapy for the management of CRSwNP\n* Capable of receiving all 3 biologic therapy medications.\n* Treatment with intranasal mometasone ≥200 μg. once daily (or equivalent of another intranasal corticosteroid) for 1-month prior to baseline visit.\n\nExclusion Criteria:\n\n* Inability or unwillingness of a participant to give written informed consent or comply with study protocol\n* Endoscopic sinus surgery within 6-months preceding enrollment \u002F randomization.\n* Oral corticosteroid use within 30-days preceding enrollment \u002F randomization.\n* Serum IgE level outside the dosing range for omalizumab (i.e., \\\u003C30 IU\u002Fml. or a weight-based dose with insufficient data to determine dose as per FDA dosing chart)\n* Comorbid atopic dermatitis, urticaria, or any other condition that would require a specific biologic per the standard of care.\n* Currently pregnant or plan to become pregnant within the 6 months after enrollment \u002F randomization.\n* Any previous treatment with any of the 3 biologic medications.\n* Comorbid cystic fibrosis, CVID, or ciliary dyskinesia.\n* Comorbid systemic inflammatory disorders (e.g., GPA, EGPA, Sarcoidosis, SLE)\n* Past or current medical problems or findings from physical examination or laboratory testing that are not listed above, which, in the opinion of the investigator, may pose additional risks for participation in the study, may interfere with the participant's ability to comply with study requirements, or that may impact the quality or interpretation of the data obtained from the study.","ALL","18 Years",{"count":20,"type":21},504,"ESTIMATED","INTERVENTIONAL",[24],"PHASE4","The prevalence of Chronic Sinusitis with Nasal Polyps (CRSwNP) in the United States is estimated at roughly 4%, which equates to over 13 million Americans. Until recently, the only medical treatment options available for patients with CRSwNP were corticosteroids, with surgery reserved for medical failure. The development of biologic medications over the last 5 years has revolutionized the treatment of CRSwNP. Three biologic medications have been FDA approved and available for the treatment of CRSwNP: dupilumab, omalizumab, and mepolizumab. However, data from the clinical trials for these drugs do not show universal improvement across all patients with CRSwNP. In fact, there is a wide range of outcomes for patients in these trials. The result is that clinicians have no way of knowing which specific biologic would be the best option for any given patient, nor do they know whether biomarkers can be used to predict response to biologics. It is hoped that findings from this study will inform whether any one biologic has superior outcomes to another and whether clinicians can identify patients at baseline who are most likely to improve on biologic therapy.",[27,28],"Chronic Sinusitis","Nasal Polyps",[30,31],"Sinusitis","Biologics","RECRUITING","2026-06-08",{"date":35,"type":36},"2026-06-09","ACTUAL",{"date":38,"type":36},"2026-06-03",{"date":40,"type":21},"2030-02",{"name":42,"class":43},"Medical University of South Carolina","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":53,"targetDuration":4,"studyType":22,"phases":55,"briefSummary":57,"conditions":58,"keywords":60,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":70,"leadSponsor":72,"locationsCount":74},"100554647","biologics-in-severe-nasal-polyposis-survey-a-french-registry-100554647","NCT06501807","BIOlogics in Severe Nasal POlyposis SurvEy.: a French Registry","Real Life Assessment of Biologics Efficacy in Severe Chronic Rhinosinusitis With Nasal Polyps","BIOPOSE2","Inclusion Criteria:\n\n* Patients of over 18-year old requiring a biologic treatment for CRswNP in accordance with its marketing approval.\n* The patients already treated according to this criteria since August 2021 will be followed and their previous clinical and biological data retrospectively collected\n\nExclusion Criteria:\n\n* Oral corticotherapy in the previous month;\n* Biologic treatment with anti-IgE (omalizumab), anti-IL-5\u002FIL-5R (mepolizumab, benralizumab) or anti-IL-4\u002FIL-13R (dupilumab) or any other biotherapy for inflammatory diseases in the previous 6 months of initiation of treatment apart from ongoing biotherapies for severe asthma or CRSwNP;\n* Hypersensitivity to humanized antibodies ;\n* Documented SARS-Cov2 infection in the last 3 months with persistent olfactory disorders related to COVID;\n* Pregnant or breast-feeding women;\n* Patient without social coverage.",{"count":54,"type":21},900,[56],"NA","With a prevalence of 2-4% in western countries, Chronic Rhinosinusitis with Nasal Polyps (CRSwNP) is of major concern regarding its substantial impact on the social and physical quality of life. So far, endoscopic sinus surgery remains the treatment of choice when the first line of medical treatment with corticosteroid has failed.\n\nDuring the last 15 years, several studies have shown that CRSwNP is associated with a T helper 2 (T2) immune response leading to B cell release of IgE, mucosal recruitment of eosinophils from bone marrow via Interleukin (IL)-5, IL-4 and IL-13 mediated chemoattractant production.\n\nNew biologic agents capable of blocking T2 cytokines have been developed in the field of eosinophil-associated diseases, shifting the paradigm of treatment for patients with CRSwNP. In the near future, endotype profiling with accurate biomarkers will be mandatory to tailor the treatment of nasal polyposis with specific biologic therapies.\n\nHerein the investigators propose a prospective study monitoring medical records of CRSwNP patients who undergo biologic treatments. The objectives are to assess treatment efficacy on quality of life, to report clinical and biological criteria for prescription and to measure tolerance and compliance.Patient-reported outcomes will be addressed according to their initial clinical profile (allergy, asthma, NSAID, gastroesophageal reflux disease, obstructive apnea, otologic disorder, smoke habit).",[59,28],"Rhinosinusitis Chronic",[61,62,63,64],"nasal polyp","chronic rhinosinusitis","eosinophil","endotype","2026-05-14",{"date":67,"type":36},"2026-05-18",{"date":69,"type":36},"2024-07-11",{"date":71,"type":21},"2035-01-02",{"name":73,"class":43},"University Hospital, Lille",2,{"id":76,"slug":77,"hasResults":11,"nctId":78,"briefTitle":79,"officialTitle":80,"acronym":4,"eligibilityCriteria":81,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":87,"lastUpdatePostDateStruct":88,"startDateStruct":90,"completionDateStruct":92,"leadSponsor":94,"locationsCount":96},"100283878","in-clinic-endoscopic-polypectomy-for-chronic-sinusitis-with-nasal-polyps-100283878","NCT02975310","In-clinic Endoscopic Polypectomy for Chronic Sinusitis With Nasal Polyps","Endoscopic Polypectomy Performed In Clinic for Chronic Rhinosinusitis With Polyps: The EPIC Randomised Controlled Trial","Inclusion Criteria:\n\n1. Age 18 years or older\n2. Diagnosis of chronic rhinosinusitis with polyps requiring surgical treatment after having been treated with medical therapy as designated by the Canadian clinical practice guidelines for acute and chronic sinusitis. 15\n3. Bilateral nasal polyps present of Grade ≥ 2 on each side as determined by the Lildholdt scale score measured by nasal endoscopy at the screening visit.\n4. Must have nasal blockage score greater than or equal to 2 on the sinonasal outcome test SNOT-22 at the screening visit.\n5. Must have an American Society of Anesthesiologists physical status PS3 classification or less.\n6. Participants with comorbid asthma or chronic obstructive pulmonary disease (COPD) must have stable disease with no exacerbations (no emergency room visits, hospitalisations, or oral or parental steroid use for these lower respiratory conditions) within 3 months before the screening visit.\n7. Must be capable, in the opinion of the investigator, of providing informed consent to participate in the study. Participants must sign an informed consent document indicating that they understand the purpose of and procedures of the study and are willing to participate in the study.\n\nExclusion Criteria:\n\n1. Women who are pregnant or breast feeding as per patient's report\n2. Patients with hyperplastic polyps or polyps large enough that they result in external nasal deformity\n3. Facial pain\u002Fpressure score higher than 2 on the sinonasal outcome test SNOT-22 at the screening visit.\n4. History of any surgical procedure that prevents the ability to accurately grade the nasal polyps\n5. Participants who will not be able to complete the follow-up appointments\u002Fevaluations\n6. Have significant oral structural abnormalities, e.g. unrepaired cleft palate\n7. Septal deviation requiring correction in order to perform either EPIC or ESS procedures\n8. Diagnosis of an immunodeficiency or immunocompromised state\n9. Diagnosis of cystic fibrosis\n10. Diagnosis of allergic fungal sinusitis\n11. Contraindication to the use of oral corticosteroids (e.g. uncontrolled diabetes, congestive heart failure, uncontrolled hypertension, known renal insufficiency, known peptic ulcer disease, known glaucoma, pregnancy)\n12. History of either Churg-Strauss syndrome, primary ciliary dyskinesia, or vasculitis (e.g. granulomatosis with polyangiitis(GPA))\n13. Allergy, hypersensitivity, or contraindication to the use of local or topical lidocaine anesthetics, nasal topical 1:1000 adrenaline, nasal decongestants, nasal steroid spray\n14. Any serious or unstable concurrent disease, psychiatric disorder, or any significant condition that, in the opinion of the investigator, could confound the results of the study or could interfere with the participant's participation or compliance with the study\n15. A recent (within 1 year of the screening visit) clinically significant history of drug or alcohol abuse, or dependence that, in the opinion of the investigator could interfere with the participant's participation or compliance with the study\n16. Inability to read and understand English\n17. Any medical condition that in the opinion of the investigator would interfere with the treatment\n18. Any participant who is unfit to undergo surgery under general anesthesia\n19. Current participation in another clinical trial at the time of the screening visit.\n20. Participant is unable to undergo an awake procedure\n21. Diagnosis or Aspirin Exacerbated Respiratory Disease (AERD)",{"count":83,"type":21},140,[56],"Chronic rhinosinusitis, also called chronic sinusitis, is a very common life-long disease affecting over 5% of the Canadian population. Its symptoms, including daily facial pain and headache, an inability to breath through the nose and complete smell loss, regularly impair one's ability to work and to enjoy and participate in daily activities. The annual cost of chronic sinusitis to Canada is estimated at $1.3 billion while the government pays an estimated $860 million yearly for chronic sinusitis treatment. Chronic sinusitis with polyps, the most common type of chronic sinusitis, is usually treated with a combination of medications and surgery. Until now, surgical treatment has only been performed in the operating room, at a cost of about $3500 per procedure. But, recent studies have shown that a new procedure, \"in-clinic polyp removal\", can provide an improvement in patient symptoms to levels equal to those for sinus surgery performed in a hospital operating room. Moreover, in clinic polyp removal has additional advantages including a shorter procedure recovery time, a significantly lower cost to the health care system (about one-tenth the cost or $450), and a shorter wait time for treatment. With the proposed pragmatic trial, the investigators will determine whether the in clinic polyp removal procedure is as good as sinus surgery in the operating room at controlling patient symptoms of chronic sinusitis. The investigators will also determine the cost and health-benefits for a patient, the healthcare system and for society of in clinic polyp removal in comparison to sinus surgery done in a hospital operating room. The investigators will then know if this new treatment, in clinic polyp removal, can replace sinus surgery as the standard of care for these patients.",[30,28],"2025-12-23",{"date":89,"type":36},"2025-12-30",{"date":91,"type":36},"2017-04-11",{"date":93,"type":21},"2026-12",{"name":95,"class":43},"Ottawa Hospital Research Institute",4,{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":102,"acronym":4,"eligibilityCriteria":103,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":104,"targetDuration":4,"studyType":22,"phases":106,"briefSummary":107,"conditions":108,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":118},"100613570","phase-4-complete-remission-after-treatment-with-biologics-for-nasal-polyps-100613570","NCT07268313","Complete Remission After Treatment With Biologics for Nasal Polyps","English Title: Complete Remission Study Subtitle: Discontinuation of Mepolizumab or Dupilumab After at Least 12 Months Without Symptoms in Patients With Severe Chronic Rhinosinusitis With Polyps - a National Danish RCT Study","Inclusion Criteria:\n\n5.1 Inclusion criteria (all must be fulfilled)\n\nInclusion criteria:\n\nAt the time when the patient started biological treatment, they must have fulfilled the EPOS criteria for initiation of biologic treatment (REF EPOS):\n\n* Fulfil the criteria for CRSwNP\n* Presence of bilateral polyps in a patient\n* Had ESS (sinus surgery) (exceptional circumstances excluded)\n* Fulfil at least three of the following five criteria Evidence of type 2 inflammation Need for (and treated with) systemic corticosteroids or contraindication to these SNOT-22 score of 40 or above Significant loss of smell Asthma needing regular inhaled corticosteroids\n\nTo enter this study, the patient must be:\n\n* Above 18 years of age\n* Currently be in treatment with either Dupilumab (300 mg) or Mepolizumab (100 mg) with treatment every fourth week. This treatment should have been stable\u002Funchanged for at least three months.\n* Within the latest year, the patient must at all times have scored all the below symptoms of CRS five or below on a VAS scale from 0 - 10 - Doing this, it is according to the EPOS defined as controlled disease. The items are: nasal blockage, rhinorrhea\u002Fpostnasal drip, facial pain\u002Fpressure, smell, sleep disturbance or fatigue) Please view appendix 2.\n* Within the latest year the nasal endoscopy cannot have showed polyp score of more than 1+1 out of 4+4, further, no thick secretions or general oedema must have been present.\n* Within the latest year the patient is not allowed to have had ESS or rescue treatment for their CRSwNP (antibiotics or systemic steroids)\n* The patient must be able to understand Danish and able to sign an informed content.\n\nExclusion Criteria:\n\n* In the twelve months of remission the patient is not allowed to have had AECRS (acute exacerbation of chronic rhinosinusitis). A common cold is allowed.\n* Polyp removal in the out-patient clinic may not have been performed within the last 3 months.\n* In the twelve months of remission the patient cannot at any time have scored higher than 1.2 on the ACQ questionnaire, meaning that the patient does not have uncontrolled asthma (Appendix 3).\n* Patients who, because of language barriers, are not able to understand written information and, thus, are not able to answer questionnaires.\n* Patients who currently receive biologics for any other disease (asthma not included)\n* Patients who are not able to give informed consent (i.e., patients who are permanently incapable)\n* Patients who are not eligible because of the investigator's judgement\n* Patients who experience pregnancy during the study will be excluded after an unscheduled visit (LOCF) - active IVF treatment. (Please look belove)\n* Patients who have or recently have had illness, such as cancer that or its treatment is expected to significantly affect morbidity and\u002For quality of life in the next two years\n* Unwillingness to follow the study procedure\n* Hypersensitivity to any of either Dupilumab or Mepolizumab.",{"count":105,"type":21},66,[24],"In this RCT the investigators randomize patients who are treated with biologic treatment (Nucala or Dupixent) due to nasal polyps and have controlled disease within the last year to either stop treatment og continue as a control group.",[28],"2025-11-25",{"date":111,"type":36},"2025-12-05",{"date":113,"type":36},"2025-04-03",{"date":115,"type":21},"2027-06-01",{"name":117,"class":43},"Rigshospitalet, Denmark",6,{"id":120,"slug":121,"hasResults":11,"nctId":122,"briefTitle":123,"officialTitle":124,"acronym":4,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":127,"targetDuration":4,"studyType":22,"phases":129,"briefSummary":130,"conditions":131,"keywords":132,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":44},"100611803","effect-of-full-house-ess-with-nasopharyngeal-lymphoid-tissue-ablation-on-nasal-polyps-100611803","NCT07245329","Effect of Full-House ESS With Nasopharyngeal Lymphoid Tissue Ablation on Nasal Polyps","Effect of Full-House Endoscopic Sinus Surgery With Versus Without Nasopharyngeal Lymphoid Ablation on Local Mucosal Inflammation in Chronic Rhinosinusitis With Nasal Polyps","Inclusion Criteria:\n\n* Aged 18-65 years\n* Diagnosed with CRSwNP according to EPOS criteria\n* Blood eosinophil count \\> 0.3 × 10⁹\u002FL\n\nExclusion Criteria:\n\n* Pregnant or lactating women.\n* Cystic fibrosis\n* primary ciliary dyskinesia\n* fungal ball rhinosinusitis\n* systemic vasculitis or granulomatous disease\n* malignancy\n* immunodeficiency.\n* Subjects with an upper-respiratory-tract infection within the past 4 weeks.\n* Clinically significant metabolic, cardiovascular, immune, neurologic, hematologic, gastrointestinal, cerebrovascular, or respiratory disorders, or any condition that, in the investigator's opinion, could interfere with outcome assessment or compromise patient safety.\n* Currently participating in another clinical trial or having participated in one within 30 days, or staff directly involved in this study.","65 Years",{"count":128,"type":21},32,[56],"This study is designed to evaluate whether the addition of nasopharyngeal lymphoid tissue ablation to full-house endoscopic sinus surgery (ESS) provides superior control of nasal mucosa inflammation compared to full-house ESS alone in patients with nasal polyps. Thirty-two adult participants will be randomly assigned to undergo either full-house ESS only or full-house ESS combined with nasopharyngeal lymphoid tissue ablation. The primary outcome will be assessed through changes in inflammatory cell profiles at 1, 3, and 6 months postoperatively. Secondary outcomes include inflammatory cytokine levels, symptom scores, endoscopic findings, polyp recurrence rates, and safety measures.",[28],[133,134],"Full-House Endoscopic Sinus Surgery","Nasopharyngeal Lymphoid Tissue Ablation","2025-11-17",{"date":137,"type":36},"2025-11-24",{"date":139,"type":36},"2025-07-01",{"date":141,"type":21},"2026-08-01",{"name":143,"class":43},"Tongji Hospital",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":152,"enrollmentInfo":153,"targetDuration":4,"studyType":22,"phases":155,"briefSummary":156,"conditions":157,"keywords":161,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":167,"lastUpdatePostDateStruct":168,"startDateStruct":170,"completionDateStruct":172,"leadSponsor":173,"locationsCount":44},"100440012","moving-towards-precision-medicine-in-united-airways-disease-unraveling-inflammatory-patterns-in-asthmatic-patients-with-or-without-nasal-polyps-100440012","NCT05009758","Moving Towards Precision Medicine in United Airways Disease: Unraveling Inflammatory Patterns in Asthmatic Patients With or Without Nasal Polyps","Moving Towards PREcision Medicine In United Airways Disease: Unraveling inflaMmatory Patterns in Asthmatic Patients With or Without Nasal Polyps (PREMIUM) - a Descriptive Pilot Study","PREMIUM","Inclusion Criteria:\n\nAll patients who\n\n* 18-99 years of age\n* have a recorded clinical diagnosis of asthma (ICD-10 Code: J45)\n* undergo moderate-serve asthma treatment according to GINA\u002FDAL treatment step 4 or step 5 without oral corticosteroid or monoclonal antibody therapy\n* Asthma treatment for a minimum of 12 weeks prior to screening visit\n\n  * Group 1 and 2 - T2-high asthma with or without polyps:\n* FeNO \\> 25 ppB\n* had either two times \\>= 250 eosinophils \u002Fµl measured in the blood OR one measurement of blood eosinophils \\>= 250 cells\u002Fµl (one of the two measurements at the screening visit) and\u002For one measurement of sputum eosinophils \\> 2% within the last 12 months\n* Group with polyps: Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and CRSwNP Guidelines)\n\n  * Group 3 - CRSwNP in absence of asthma:\n* Presence of CRSwNP as confirmed by endoscopy or CT according to the European Position Paper on Rhinosinusitis and Nasal Polyps Guidelines\n* Evidence of Type 2 inflammation: eosinophils \\>= 250 cells\u002Fµl measured in the blood OR total IgE \\>100 kU\u002FL at the screening visit\n* Absence of asthma and N-ERD\n* Patients with a history of treatment with monoclonal antibodies for asthma or polyps will only be included if at least a wash out period of 5 half-lives or at least 3 months have passed\n\nExclusion Criteria:\n\n* Pregnancy (as determined by ß-HCG test)\n* Patients with severe anatomic variations or deviations that do not allow access to all areas in the nasal cavity\n* Patients undergoing chronic oral corticosteroid therapy\n* Patients with any other confounding underlying lung disorder including but not limited to:\n\n  * Bronchiectasis, chronic obstructive pulmonary disorder (COPD), pulmonary fibrosis, emphysema, primary ciliary dyskinesia\n  * Cystic fibrosis, any known parasitic infections, and lung cancer\n* Patients with pulmonary conditions with symptoms of asthma and blood eosinophilia including but not limited to: Eosinophilic granulomatosis with polyangiitis (EGPA), allergic bronchopulmonary aspergillus, and hypereosinophilic syndrome\n* A mental condition rendering the subject unable to understand the nature, scope, and possible consequences of the study\n* Patients with clinically meaningful comorbidity as determined by the evaluating committee\n* Patients with a history of exacerbation of chronic rhinosinusitis or asthma 4 weeks prior to any visit\n* Intake of a burst of systemic corticosteroids 4 weeks prior to any visit.\n* Immunosuppressive treatment (e.g. cyclosporine)\n* Drug and alcohol abuses\n* Current smoker\n* Former smoker if stopped smoking \\\u003C6 months and\u002For has \\>10 pack-years","99 Years",{"count":154,"type":21},30,[56],"Asthma and chronic rhinosinusitis (CRS) are inflammatory diseases of the respiratory tract, asthma from the lower part, and CRS, from the upper part. In theory, these parts are correlated as if they are one single organ, namely \"united airways\", which means that if one is affected by any condition, the other might be impacted as well. However, this relationship has not yet been described down to the cellular and molecular levels. By investigating patients that have (1) asthma and CRS with nasal polyp, (2) asthma and CRS without nasal polyp, and (3) just CRS with nasal polyp, we aim to determine the correlation of the upper and lower part of the respiratory tract. At first, the characterization of disease will be determined by established clinical criteria, such as lung function, blood analysis for the presence of eosinophils (a type of white cells), and nasal polyp score. To continue, in-depth analysis of nose, oropharynx, and lung samples will help gain information about the inflammatory profile and local microbiome of the three different groups of patients through molecular and cellular assays. The results of this study will help to describe the hypothesis of the united airways which will provide better guidance for medical treatment of asthma and CRS with or without polyp, thus improving the life quality of patients.",[158,159,160,28],"Asthma","Chronic Rhinosinusitis With Nasal Polyps","Chronic Rhinosinusitis (Diagnosis)",[158,162,163,164,165,166],"Chronic Rhinosinusitis (CRS)","CRS with Nasal Polyps","CRS without Nasal Polyps","Inflammatory profile","Type 2 inflammation","2025-05-06",{"date":169,"type":36},"2025-05-07",{"date":171,"type":36},"2021-09-01",{"date":93,"type":21},{"name":174,"class":43},"Medical University of Vienna",{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":4,"eligibilityCriteria":181,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":126,"enrollmentInfo":182,"targetDuration":4,"studyType":22,"phases":184,"briefSummary":185,"conditions":186,"keywords":188,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":199,"locationsCount":44},"100446525","phase-4-interleukin-4ra-blockade-by-dupilumab-decreases-staphylococcus-colonization-and-increases-microbial-diversity-in-crswnp-100446525","NCT05094570","Interleukin-4Ra Blockade by Dupilumab Decreases Staphylococcus Colonization and Increases Microbial Diversity in CRSwNP","Interleukin-4Ralpha Blockade by Dupilumab Decreases Staphylococcus Aureus Colonization and Increases Microbial Diversity in Chronic Rhinosinusitis With Nasal Polyposis (CRSwNP)","Inclusion Criteria: • Adults, ages 18-65\n\n* History of CRSwNP including subjects with AERD\n* Sinonasal culture demonstrating staph aureus at visit 1\n* History of FESS with patent sinus ostia sufficient to obtain culture and tissue samples from the middle meatus\n* Asthma, if present, should be well controlled\n* Atopic dermatitis, if present, should be well controlled\n* Use of nasal saline irrigation and stable dosing (\\>1 month) of topical corticosteroids is permitted\n* Intent of the physicians caring to start dupilumab therapy as part of subject's standard of care\n* Subject meets FDA approved criteria for the use of dupilumab for nasal polyps\n\nExclusion Criteria:\n\n* Concurrent serious medical problem\n* Uncontrolled asthma (ACT \\\u003C20 at screening visit)\n* Recent (within 60 days) use of oral corticosteroids\n* Recent (within 60 days) urgent care, ED visit, or hospitalization for asthma\n* Current smoker or has smoked \\>10 pack-years\n* Biologic therapy including asthma biologic therapy in last 3 months\n* Recent (within 1 month) change in CRS medical treatment (topical steroids, surfactants, irrigation protocol, etc. including changes in delivery volume or delivery methodology)\n* Recent (within 6 weeks) upper respiratory infection\n* Antibiotics within 6 weeks\n* Pregnant or breast-feeding women\n* Any contraindication to the use of dupilumab including hypersensitivity on previous administration",{"count":183,"type":21},20,[24],"Hypothesis: The investigators hypothesize that in patients with CRSwNP who demonstrate sinus colonization with staphylococcus aureus, the administration of dupilumab will be associated with decreased staph colonization and an increase in microbial diversity.\n\nPrimary Objective will be to demonstrate that dupilumab reduces staphylococcus aureus (phyla firmicutes) abundance while increasing microbial diversity in patients with CRSwNPs who are culture positive for staph aureus at enrollment.\n\nSecondary Objectives will be to correlate reduction in Staph aureus abundance and improved bacterial diversity with increased expression of anti-microbial proteins (ß-defensins1-4) and cathelicidin LL-37. In addition, the investigators will correlate improvements in microbial diversity\u002Fdecreased staph abundance with clinical improvements as assessed via questionnaires and objective\u002Fsubjective smell function and also as improvements in cellular\u002Fimmune T2 inflammation as assessed by reduced expression of T2 cytokines\u002Fchemokines and eosinophil\u002Feosinophil-derived proteins.",[28,187],"Staphylococcus Aureus",[189,190,191],"Nasal polyps","Staph aureus","Interleukin-4\u002F-13","2025-03-26",{"date":194,"type":36},"2025-04-01",{"date":196,"type":36},"2022-09-01",{"date":198,"type":21},"2026-12-31",{"name":200,"class":43},"University of Virginia",{"id":202,"slug":203,"hasResults":11,"nctId":204,"briefTitle":205,"officialTitle":206,"acronym":4,"eligibilityCriteria":207,"healthyVolunteers":208,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":209,"targetDuration":4,"studyType":22,"phases":211,"briefSummary":212,"conditions":213,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":218,"lastUpdatePostDateStruct":219,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":227},"100461376","does-batten-grafting-improve-nasal-outcomes-in-septoplasty-and-turbinate-reduction-100461376","NCT05287841","Does Batten Grafting Improve Nasal Outcomes in Septoplasty and Turbinate Reduction?","Does the Addition of Batten Grafting Improve Nasal Outcomes in Patients Undergoing Septoplasty and Turbinate Reduction? A Pragmatic Randomized Controlled Trial","Inclusion Criteria:\n\n* Patients should satisfy all the following criteria to be considered eligible for randomization:\n\n  1. Be age 18 or above\n  2. Able to provide written informed consent\n  3. Have an indication for batten graft, septoplasty and turbinate reduction according to prevailing surgical practices.\n\n  \u003C!-- -->\n\n  1. Septal deviation must be present on direct or endoscopic examination\n  2. Inferior turbinate hypertrophy must be present, direct examination or endoscopic examination\n  3. Collapse of external nasal valve and\u002For lateral motion instability must be documented\n\n  \u003C!-- -->\n\n  1. The ENV maye be assessed clinically by observing the alar collapse at baseline or with forced inspiration, Modified cottle may also be performed.\n\nIn all patients, endoscopic examination should document that the (a) septal deviation, (b) turbinate hypertrophy, and (c) external nasal valve collapse are the primary contributing factors of obstructed breathing.\n\nExclusion Criteria:\n\n1. Septal perforation\n2. History of previous functional rhinoplasty or sinus or septal surgery\n3. Patients who are selected for concurrent aesthetic\u002Fcosmetic rhinoplasty\n4. Untreated allergic rhinitis or allergic rhinitis unresponsive to medical management\n5. Patients who have concurrent sinus surgery or polyp removal or concha bullosa resection",true,{"count":210,"type":21},96,[56],"The objective of this study is to compare the effectiveness of batten grafts plus septoplasty and turbinate reduction (intervention arm) compared to septoplasty and turbinate reduction alone (control arm), both in terms of subjective and objective assessments.",[214,215,216,28,217],"Nasal Obstruction","Septal Defect","Allergic Rhinitis","Nasal Valve Collapse","2024-09-18",{"date":220,"type":36},"2024-09-20",{"date":222,"type":36},"2021-04-30",{"date":224,"type":21},"2025-06-15",{"name":226,"class":43},"Northwell Health",3,{"id":229,"slug":230,"hasResults":11,"nctId":231,"briefTitle":232,"officialTitle":232,"acronym":4,"eligibilityCriteria":233,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":234,"targetDuration":4,"studyType":22,"phases":236,"briefSummary":237,"conditions":238,"keywords":4,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":240,"lastUpdatePostDateStruct":241,"startDateStruct":243,"completionDateStruct":245,"leadSponsor":247,"locationsCount":44},"100543918","anatomo-clinico-biological-profiles-in-severe-nasal-polyps-100543918","NCT06362122","Anatomo-clinico-biological Profiles in Severe Nasal Polyps","Inclusion Criteria:\n\n* Patient ≥ 18 year-old\n* Patient with nasal sinus polyposis resistant to medical treatment and requiring surgical treatment with ethmoidectomy type is considered for the first time\n* Having signed the consent form\n* Having an health insurance\n\nExclusion Criteria:\n\n* Current or past biotherapy treatment\n* Taking general corticosteroid therapy within 4 weeks of surgery\n* Protected person\n* Pregnant women or lactating women",{"count":235,"type":21},200,[56],"Nasal sinus polyposis is a chronic inflammatory pathology of the nasal cavity and sinus cavities that causes bilateral and multifocal polyp development and has a prevalence of 2 to 4% in the general population.\n\nTherapeutic management consists of first-line medical treatment for anti-inflammatory purposes. Local corticosteroid therapy, using nasal sprays, is the background treatment. Surgical management is offered to patients in case of failure of medical treatment. Although effective, surgery does not protect patients from recurrence of symptoms related to regrowth of polyps. Recently, biologics have appeared, which despite its effectiveness, about 20% of patients have a partial or no response to these treatments. There is currently no possibility of determining the probability of response to treatments in patients.\n\nIt is therefore essential to determine an anatomo-clinico-biological correlation associating the anatomopathological profile, the clinical characteristics and the cytokine signature in order to best guide the patient's management, including the initiation of biotherapy. Indeed, patients, according to their clinical, biological characteristics and the cytokine signature of their polyps will react differently to different treatments, including surgery and biotherapy. This correlation will serve as a predictor of treatment response.",[239],"NASAL POLYPS","2024-06-07",{"date":242,"type":36},"2024-06-10",{"date":244,"type":36},"2024-06-03",{"date":246,"type":21},"2026-10-03",{"name":248,"class":43},"Poitiers University Hospital"]